» Articles » PMID: 39001493

Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis?

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Jul 13
PMID 39001493
Authors
Affiliations
Soon will be listed here.
Abstract

In this multicenter, retrospective study, we evaluated the added value of magnetic resonance dispersion imaging (MRDI) to standard multiparametric MRI (mpMRI) for PCa detection. The study included 76 patients, including 51 with clinically significant prostate cancer (csPCa), who underwent radical prostatectomy and had an mpMRI including dynamic contrast-enhanced MRI. Two radiologists performed three separate randomized scorings based on mpMRI, MRDI and mpMRI+MRDI. Radical prostatectomy histopathology was used as the reference standard. Imaging and histopathology were both scored according to the Prostate Imaging-Reporting and Data System V2.0 sector map. Sensitivity and specificity for PCa detection were evaluated for mpMRI, MRDI and mpMRI+MRDI. Inter- and intra-observer variability for both radiologists was evaluated using Cohen's Kappa. On a per-patient level, sensitivity for csPCa for radiologist 1 (R1) for mpMRI, MRDI and mpMRI+MRDI was 0.94, 0.82 and 0.94, respectively. For the second radiologist (R2), these were 0.78, 0.94 and 0.96. R1 detected 4% additional csPCa cases using MRDI compared to mpMRI, and R2 detected 20% extra csPCa cases using MRDI. Inter-observer agreement was significant only for MRDI (Cohen's Kappa = 0.4250, = 0.004). The results of this study show the potential of MRDI to improve inter-observer variability and the detection of csPCa.

Citing Articles

A Deep Learning-Based Framework for Highly Accelerated Prostate MR Dispersion Imaging.

Zhao K, Pang K, Hung A, Zheng H, Yan R, Sung K Cancers (Basel). 2024; 16(17).

PMID: 39272841 PMC: 11393971. DOI: 10.3390/cancers16172983.

References
1.
Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

2.
van Leenders G, van der Kwast T, Grignon D, Evans A, Kristiansen G, Kweldam C . The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020; 44(8):e87-e99. PMC: 7382533. DOI: 10.1097/PAS.0000000000001497. View

3.
Wei J, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R . Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023; 210(1):54-63. PMC: 11321723. DOI: 10.1097/JU.0000000000003492. View

4.
van Dorsten F, van der Graaf M, Engelbrecht M, van Leenders G, Verhofstad A, Rijpkema M . Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004; 20(2):279-87. DOI: 10.1002/jmri.20113. View

5.
Bass E, Pantovic A, Connor M, Gabe R, Padhani A, Rockall A . A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. Prostate Cancer Prostatic Dis. 2020; 24(3):596-611. DOI: 10.1038/s41391-020-00298-w. View